High-Potency Vitamin D Comes in a Softgel
Research shows that Vitamin D may protect against a number of ailments, including osteoporosis, diabetes, glucose intolerance,hypertension, stroke, autoimmune diseases and some forms of cancer. Vitamin D is naturally synthesized in the skin following exposure to sunlight, but deficiencies may occur as a result of decreased time spent outdoors, reduced sun exposure in colder climates and heavy use of sunscreen. Cardium Therapeutics has introduced a high-potency bioavailable Vitamin D supplement, D-Sorb. provides 2000 IUs of Vitamin D3 in softgels .A lipid-based delivery system allows the Vitamin D to become more water soluble, which has been clinically proven to provide increased absorption and bioavailability. Vesisorb D-Sorb colloidal droplets also protect the Vitamin D from light oxidation and stomach acids. D-Sorb utilizes Vitamin D3, which is considered to be a more effective form of Vitamin D than Vitamin D2. Vitamins D2 (ergocalciferol) and D3 (cholecalciferol) are both naturally occurring precursors that are converted in the liver and kidneys to the biologically active form of Vitamin D. Studies have shown that Vitamin D3 is more effective than Vitamin D2 in raising and maintaining levels of biologically active Vitamin D.cardiumthx.com
Making Progress on a New Drug for Overactive Bladder
Astellas Pharma Inc. (Tokyo) is seeking U.S. Food and Drug Administration and European Medicines Agency approval for mirabegron (generic name/code name: YM178) for the first in a new class of medicine for the indication of overactive bladder (OAB) associated with symptoms of urgency, urinary frequency, and urge urinary incontinence.Phase 3 clinical trials in the U.S. and Europe met primary endpoints compared to placebos.
A once daily oral selective B3-adrenoceptor agonist discovered by Astrellas, mirabegron is being developed for international markets .In Japan, In Japan, Astellas was approved for marketing under the trade name Betanis tablet in July 2011. Underway is a multiregional Phase 3 study in China, Korea, Taiwan, and India. Astellas markets the popular OAB medication solifenacin succinate (known as VESIcare) in 67 countries.
Vesicare tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The recommended dose of Vesicare is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily.VesiIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product.